The Effect Of MiR-155 On The Prognosis Of DLBCL In The Era Of Rituximab

OBJECTIVE: The use of rituximab as a standard of initial therapy in addition to conventional chemotherapy,as well as the use of high-dose chemotherapy and relapsed DLBCL in autologous stem cell transplantation strategies,has resulted in a significant improvement in the prognosis of DLBCL.Detection of microRNAs improved detection and staging of DLBCL can provide a more accurate assessment of the response to treatment.Based on the existing R-CHOP,whether it can improve the response of patients by further inhibiting the expression of microRNA,in order to improve the prognosis of patients.This article focuses on the analysis of the impact of miR-155 on the prognosis of DLBCL in the era of Meritus.METHODS: Lymph node tissue samples of patients with diffuse large B-cell lymphoma and normal persons were collected.miR-155 level was detected by Real-time PCR,STAT3 pathway and apoptosis protein expression level was detected by Western blot,and IL-6 expression level was detected by ELISA.Lymphoma tissue STAT3 and Ki67 expression levels were detected by immunohistochemical.We used SPSS to analyze its relevance.RESULTS: Normal lymphatic tissue miR-155 levels were significantly lower than those of DLBCL patients.In patients with DLBCL,the IPI score was >2 points.The level of miR-155 in patients with DLBCL was significantly higher than those with IPI score <2.Patients with IPI4 score had lower STAT3,p-STAT3 expression than patients with IPI1 score,Cleaved Caspase3,Cleaved Caspase7,patients with Cleaved PARP expression higher than IPI1 score.In patients with high expression of miR-155,the expression of apoptotic protein increased and the expression of STAT3 and p-STAT3 was low.The expression of IL-6was positively correlated with the expression of STAT3,p-STAT3 and negatively correlated with the expression of miR-155.Immunohistochemistry confirmed that the expression of STAT3 was elevated and Ki67 expression was elevated in patients with high miR-155 expression.In patients with low expression of miR-155,the use of rituximab can achieve better remission in patients with DLBCL.CONCLUSION:miR-155 may play an oncogene role in DLBCL by regulating the effect of IL-6 by STAT3 pathway.miR-155 may be closely related to the high proliferation and metastasis of tumors..